-
LDH Cytotoxicity Assay Kit: Practical Workflow
2026-09-21
The LDH Cytotoxicity Assay Kit provides a non-radioactive approach to cell cytotoxicity measurement by detecting LDH released after loss of plasma-membrane integrity. It is useful for comparative cell damage quantification, but LDH release alone should not be used to assign a specific death pathway or replace controls for compound, medium, and optical interference.
-
APOL1 Evolution, Isoforms, and APOL3 Interaction
2026-09-20
The 2025 review by Khalaila and Skorecki integrates APOL1 molecular evolution, splice-isoform biology, and APOL3 interaction data to refine explanations for variant-associated cellular injury. Its main practical implication is that APOL1 renal toxicity should be studied as a context-dependent property shaped by haplotype, isoform, and protein–protein interaction rather than by risk alleles alone.
-
SB 431542: Precision ALK5 Inhibitor Workflows
2026-09-19
Use SB 431542 to separate ALK5-dependent TGF-β signaling from cell-state and immune-cell effects in primary and transformed models. This workflow translates a primary HLA-G+ extravillous trophoblast platform into practical pathway-validation, co-culture, and troubleshooting strategies.
-
Pseudo-UTP: From IVT to Functional RNA
2026-09-18
Pseudo-UTP can improve the performance profile of RNA produced by in vitro transcription, but its value is best judged through a linked chain of biochemical, cellular, and formulation assays. This article presents a decision framework connecting pseudouridine chemistry with mRNA vaccine development, gene therapy RNA modification, and emerging LNP-enabled immunotherapy.
-
N1-Methylpseudouridine and Translation Fidelity
2026-09-18
The reference study shows that N1-methylpseudouridine, the modified nucleoside used in COVID-19 mRNA vaccines, does not substantially disrupt ribosomal decoding or increase miscoded peptides. Its combined translation, RNA-structure, and reverse-transcription experiments distinguish improved RNA performance from translational accuracy, providing a useful framework for mRNA vaccine development and RNA translation mechanism research.
-
CTOP (B5135) for μ-Opioid Receptor Studies
2026-09-17
Learn how CTOP (SKU B5135) can strengthen μ-opioid receptor experiments by separating receptor-dependent signaling from viability or cytotoxicity readouts. This scenario-based guide covers experimental controls, peptide handling, data interpretation, and practical supplier selection.
-
Dimethyloxalylglycine (DMOG) Protocol Guide
2026-09-17
Dimethyloxalylglycine (DMOG), SKU A4506, is a cell-permeable competitive PHD inhibitor for hypoxia-inducible factor stabilization in controlled research workflows. This guide covers concentration selection, solubility, storage, controls, and QC; it is not a diagnostic, therapeutic, or clinical protocol, and no directly matched paper evidence is available for this product entry.
-
TCAIM, OGDH, and Mitochondrial Metabolism
2026-09-16
A 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds OGDH and lowers its abundance through HSPA9 and LONP1. The work establishes a noncanonical proteostasis mechanism for regulating OGDH complex activity and mitochondrial carbohydrate metabolism in cells and mice.
-
CTOP for μ-Opioid Receptor Research
2026-09-16
CTOP provides a reversible pharmacological way to test whether μ-opioid receptor activity drives opioid signaling, mechanical hypersensitivity, or analgesic tolerance. This workflow connects receptor assays with the brain-to-spinal circuit findings reported in recent pain research while emphasizing controls, handling, and interpretation.
-
CTOP: Mapping μ-Opioid Pain Signaling
2026-09-15
CTOP is a selective μ-opioid receptor antagonist for dissecting receptor-dependent signaling in pain models. This article explains how to use CTOP as a causal assay variable when investigating the brain-to-spinal mechanisms of opioid-induced mechanical hypersensitivity and tolerance.
-
CTOP for μ-Opioid Receptor Research
2026-09-15
CTOP provides a selective pharmacological checkpoint for separating μ-opioid receptor-dependent effects from downstream circuit activity in binding, signaling, and pain assays. This workflow-oriented guide shows how to prepare, apply, and troubleshoot CTOP when investigating mechanical hypersensitivity, opioid tolerance, and brain-to-spinal pain mechanisms.
-
Indazole/Indole Glucagon Receptor Antagonists
2026-09-14
The reference study describes a medicinal chemistry series that replaces the pyrazole-centered architecture of MK-0893 with indazole, indole, and related azaindole scaffolds. Structure–activity relationship studies produced potent glucagon receptor antagonists, including GRA 16d, which reduced glucagon-driven glucose excursions in humanized-receptor mouse models after oral dosing.
-
Radicicol for Mitochondrial Senescence Assays
2026-09-14
Radicicol, a potent Hsp90 inhibitor and ATPase/kinase probe, can sharpen interpretation of mitochondrial stress and inflammatory senescence experiments. This article connects its biochemical profile with the α-KG–LKB1–AMPK findings in periodontal stem cells while defining practical controls and experimental limits.
-
PEDV Hijacks IMPDH-Dependent Nucleotide Synthesis
2026-09-13
A recent study identifies IMPDH2-dependent guanine nucleotide biosynthesis as a host metabolic requirement for porcine epidemic diarrhea virus replication. By combining untargeted metabolomics with genetic knockdown and merimepodib inhibition, the work supports IMPDH as a host-directed antiviral target while revealing cell-type-specific metabolic responses to PEDV infection.
-
PP 1: Src Family Tyrosine Kinase Inhibitor Guide
2026-09-12
PP 1 enables controlled interrogation of Lck, Fyn, Lyn, and related Src-family signaling in cancer and immune-cell assays. This practical guide connects dose design, phospho-readouts, RET transformation models, T-cell activation modulation, and mechanism-focused troubleshooting.